Skip to main content
. 2012 Sep 11;10(1):75–82. doi: 10.3109/1547691X.2012.711783

Figure 4. .

Figure 4. 

Intracellular IFN-γ staining of human PBMC stimulated for 24 h with 1 μg/well of immobilized TGN1412, Rituximab, Muromonab, and Campath-1H. CD4+ T cells, CD8+ TT cells and NK cells are identified using the key above. TGN1412 stimulates IFN-γ secretion from CD4+ T-cells, Rituximab, and Campath-1H stimulate IFNγ secretion from NK cells and CD8+ T-cells and Muromonab stimulate IFN-γ secretion from CD4+ and CD8+ T-cells and NK cells.